Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• EML4-ALK fusion gene in 8% of non-small cell lung cancer (NSCLC) contributes to treatment failure.
• Drug resistance in NSCLC can be overcome by targeting secondary mutations in ALK protein.
• Targeting ALK and microRNA-301 offers a novel therapeutic strategy for NSCLC.

Purpose of the Study:

• To develop a gold nanoshell (HAuNs) drug carrier for targeted gene and drug delivery in NSCLC.
• To investigate a multidimensional treatment strategy combining gene therapy, photothermal therapy, and chemotherapy.
• To evaluate the efficacy of a novel nano-formulation for EML4-ALK-positive NSCLC treatment.

Main Methods:

• Development of gold nanoshells for drug and gene delivery.
• Loading of doxorubicin (DOX) onto nanoshells for chemotherapy.
• Selective photo-thermal release of genes targeting ALK and microRNA-301.
• RGD peptide modification for enhanced tumor targeting.
• In vitro and in vivo evaluation of the nanoshell system's therapeutic effects.

Main Results:

• The dual-target gene therapy (ALK mRNA and microRNA-301) showed a combined therapeutic effect.
• The gold nanoshell system enhanced drug accumulation in tumor tissues via photothermal effect and RGD modification.
• Multidimensional therapy using the gold nanoshell system demonstrated superior efficacy compared to monotherapy.
• In vitro and in vivo studies confirmed the effectiveness of the nano-formulation.

Conclusions:

• The developed gold nanoshell-based system is a promising platform for treating EML4-ALK-positive NSCLC.
• This multidimensional approach offers a potential strategy to overcome NSCLC drug resistance.
• The nano-formulation represents a significant advancement in translational nanomedicine for targeted cancer therapy.